Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Samples from the coronavirus vaccine trials are handled inside the Oxford Vaccine Group laboratory in Oxford, England, on June 25, 2020.

John Cairns/The Associated Press

Researchers at Oxford University have released promising test results for a COVID-19 vaccine, which uses a novel technology based on a cold virus found in chimps, and said the drug could be in use by the end of the year.

A team at Oxford’s Jenner Institute has been working on the vaccine since January and the group has already signed a deal with pharmaceutical giant AstraZeneca PLC to make two billion doses within 12 months. On Monday, the scientists released results from the first phase of tests involving 1,077 volunteers in Britain.

“The early stage trial finds that the vaccine is safe, causes few side effects, and induces strong immune responses,” said a report on the findings published in The Lancet medical journal.

Story continues below advertisement

The results showed that the vaccine stimulated two key parts of the body’s immune system – antibodies and T-cells. Antibodies try to neutralize viruses when they first enter the body while T-cells destroy any cells that have already been infected by the virus. An ideal vaccine needs to activate both in order to provide long-lasting immunity.

It’s been six months since COVID-19 came to Canada. Here are some of the lives we’ve lost

“We’re encouraged by what we’re seeing and these are at the high end of what our expectations might have been say six months ago,” said Adrian Hill, the director of the institute. “It’s possible there will be a vaccine being used by the end of the year.”

He added that the vaccine is undergoing further tests on more than 40,000 people in Britain, the U.S., South Africa and Brazil. Results from those tests are expected this fall and if successful, the vaccine could be approved for limited use by December.

Many other scientists welcomed the Oxford results but also cautioned against overoptimism. “Developing new vaccines is a highly complicated process and success is by no means assured,” said Doug Brown, chief executive of the British Society for Immunology.

“Although the results of this trial are an important step forward, they are not the end of the story,” he said. “The researchers still have many more stages to go through before we can confirm that this vaccine is safe and effective for widespread use against [COVID-19].”

British Prime Minister Boris Johnson also applauded the Oxford group on Monday and struck a note of warning. “It may be that the vaccine is going to come riding over the hill like the cavalry. But we just can’t count on it right now,” he said.

There are more than 100 vaccine projects around the world and some in China and the U.S. have also shown early promise. Several countries have begun to hedge their bets and place orders with more than one vaccine developer.

Story continues below advertisement

On Monday, the British government said it had ordered 90 million doses of potential vaccines from companies in Germany and France. That was in addition to the 100 million doses of the Oxford drug Britain plans to buy from AstraZeneca. The U.S. government has secured orders for millions doses of the Oxford drug as well as one being developed by Boston-based Moderna Inc., while Canada is spending $192-million on producing a Canadian-made vaccine.

In the Oxford vaccine effort, a cold virus found in chimpanzees is genetically altered to make it harmless to humans and then engineered to produce the same spike-like proteins that the COVID-19 virus uses to infect humans.

Once injected as a vaccine, it primes the body’s immune system to recognize and attack COVID-19. The central mechanism – known as ChAdOx – has already served as a platform for vaccines for Ebola and other coronavirus diseases such as Middle East respiratory syndrome.

While the early testing has gone well, there remain plenty of unanswered questions. The researchers have yet to see how the vaccine works on older adults and it’s not clear whether one or two doses will be needed. The early testing also found no adverse side effects, according to The Lancet, but many volunteers reported some fatigue and headaches, which were managed with paracetamol.

“There’s still a long way to go,” said Sarah Gilbert, one of the Oxford researchers. “The difficulty that we have and that all vaccine developers have in trying to make a vaccine against this particular virus is that we don’t know how strong that immune response needs to be.

“So we can’t say just by looking at the immune responses whether this is going to protect people or not. The only way we are going to find out is by doing the large phase trial and waiting for people to be infected as part of that trial before we know if the vaccine can work.”

Story continues below advertisement

Dr. Hill said the world will need more than one vaccine and he called on researchers to work together. “We would really like to see different vaccines being tested in the same lab by the same people, so the world has a really direct comparison of the performance of different vaccines,” he said. “We do want the best vaccine.”

AstraZeneca has promised to make the Oxford vaccine available at cost during the pandemic and it has been working with manufacturers in several countries.

Monday’s data “increases our confidence that the vaccine will work and allows us to continue our plans to manufacture the vaccine at scale for broad and equitable access around the world,” said Mene Pangalos, AstraZeneca’s head of biopharmaceuticals research and development.

The company’s shareholders have already reaped some benefits from the vaccine program; AstraZeneca’s share price has soared 46 per cent this year on the London Stock Exchange.

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies